Cyclerion Therapeutics CYCN Stock
Cyclerion Therapeutics Price Chart
Cyclerion Therapeutics CYCN Financial and Trading Overview
| Cyclerion Therapeutics stock price | 4.25 USD |
| Previous Close | 4.96 USD |
| Open | 4.53 USD |
| Bid | 3.25 USD x 200 |
| Ask | 5.31 USD x 200 |
| Day's Range | 4.08 - 4.53 USD |
| 52 Week Range | 1.03 - 8.48 USD |
| Volume | 101.69K USD |
| Avg. Volume | 39.45K USD |
| Market Cap | 19.9M USD |
| Beta (5Y Monthly) | 1.755 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.68 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
CYCN Valuation Measures
| Enterprise Value | 18.19M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2442749 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 10.471443 |
| Price/Book (mrq) | 3.5564852 |
| Enterprise Value/Revenue | 9.574 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Cyclerion Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.755 |
| 52-Week Change | 88.05% |
| S&P500 52-Week Change | 18.83% |
| 52 Week High | 8.48 USD |
| 52 Week Low | 1.03 USD |
| 50-Day Moving Average | 3.75 USD |
| 200-Day Moving Average | 2.55 USD |
CYCN Share Statistics
| Avg. Volume (3 month) | 39.45K USD |
| Avg. Daily Volume (10-Days) | 107.35K USD |
| Shares Outstanding | 4.68M |
| Float | 1.18M |
| Short Ratio | 2.2 |
| % Held by Insiders | 21.70% |
| % Held by Institutions | 70.86% |
| Shares Short | 52.39K |
| Short % of Float | 1.33% |
| Short % of Shares Outstanding | 1.11% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -359.15% |
| Gross Margin | 15.94% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -52.33% |
| Return on Equity (ttm) | -98.22% |
Income Statement
| Revenue (ttm) | 1.9M USD |
| Revenue Per Share (ttm) | 0.49 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 303K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -6707000 USD |
| Diluted EPS (ttm) | -1.66 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.39M USD |
| Total Cash Per Share (mrq) | 0.3 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.821 |
| Book Value Per Share (mrq) | 1.195 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4451000 USD |
| Levered Free Cash Flow (ttm) | -2075000 USD |
Profile of Cyclerion Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 First Street, Riverview II |
| ZIP | 02142 |
| Phone | 857 327 8778 |
| Website | https://www.cyclerion.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Q&A For Cyclerion Therapeutics Stock
What is a current CYCN stock price?
Cyclerion Therapeutics CYCN stock price today per share is 4.25 USD.
How to purchase Cyclerion Therapeutics stock?
You can buy CYCN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cyclerion Therapeutics?
The stock symbol or ticker of Cyclerion Therapeutics is CYCN.
Which industry does the Cyclerion Therapeutics company belong to?
The Cyclerion Therapeutics industry is Biotechnology.
How many shares does Cyclerion Therapeutics have in circulation?
The max supply of Cyclerion Therapeutics shares is 4.68M.
What is Cyclerion Therapeutics Price to Earnings Ratio (PE Ratio)?
Cyclerion Therapeutics PE Ratio is now.
What was Cyclerion Therapeutics earnings per share over the trailing 12 months (TTM)?
Cyclerion Therapeutics EPS is -1.68 USD over the trailing 12 months.
Which sector does the Cyclerion Therapeutics company belong to?
The Cyclerion Therapeutics sector is Healthcare.
Cyclerion Therapeutics CYCN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26506.99 USD — |
-0.29
|
5.67B USD — | 26444.84 USD — | 26628.58 USD — | — - | 5.67B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13020.26 USD — |
-0.3
|
— — | 12989.73 USD — | 13083.15 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1355.67 USD — |
-0.65
|
— — | 1350.2 USD — | 1357.39 USD — | — - | — — |
- {{ link.label }} {{link}}
